Research
Hormonal
Continuing GLP-1 or GIP agonists before upper endoscopy increases the risk of clinically significant residual gastric volume (RGV).
Practitioners should consider holding GLP-1 or GIP agonists prior to upper endoscopy to reduce the risk of RGV.
StrongSupportsmedium confidence
Clinically significant RGV occurred in 3.1% in the hold group vs 25.0% in the continue group (absolute difference, 21.9% [90% CI, 7.0%-36.7%]; P = .003).
Why this rating
Based on a randomized clinical trial design.
Source
Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Akram I. Ahmad et al. · JAMA Internal Medicine · 2026
rct · n=60Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →